𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Certolizumab pegol therapy of rheumatoid arthritis: Overview

✍ Scribed by Ines Zidi; Wissem Mnif; Aicha Bouaziz; Nidhal Ben Amor

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
118 KB
Volume
72
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

American College of Rheumatology hybrid
American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: Data from a 52-week phase III trial
✍ R. F. van Vollenhoven; D. Felson; V. Strand; M. E. Weinblatt; K. Luijtens; E. C. πŸ“‚ Article πŸ“… 2010 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 101 KB πŸ‘ 2 views

## Abstract ## Objective The American College of Rheumatology (ACR) hybrid (a modified mean percent response to treatment) was officially recommended by the ACR as a revision to 20%, 50%, and 70% response criteria (ACR20/50/70) scores, but has not been tested in clinical trials. We performed a pos

Laser therapy of rheumatoid arthritis
Laser therapy of rheumatoid arthritis
✍ John A. Goldman; Joseph Chiapella; Noah Bass; Jimmy Graham; William McClatchey; πŸ“‚ Article πŸ“… 1980 πŸ› John Wiley and Sons 🌐 English βš– 604 KB

## Abstract Thirty people with classical or definite rheumatoid arthritis received laser exposure to a Q‐switch neodymium laser that operated at 1.06 ΞΌm with an output of 1 5 joules/cm^2^ for 30 nsec. One hand was lased at the proximal interphalangeal (PIP) and metacarpal phalangeal (MCP) joints, w

Dose escalation of certolizumab pegol fr
Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: An analysis of individual patient-level data
✍ Jeffrey R. Curtis; L. Chen; K. Luijtens; I. Navarro-Millan; N. Goel; L. Gervitz; πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 107 KB

## Abstract ## Objective To determine whether certolizumab pegol (CZP) dosage escalation from 200 mg to 400 mg every other week benefits some patients with rheumatoid arthritis (RA). ## Methods In the extension of the Rheumatoid Arthritis Prevention of Structural Damage 1 (RAPID 1) study into an

Efficacy and safety of certolizumab pego
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
✍ Alain M. Schoepfer; Stephan R. Vavricka; Janek Binek; Christian Felley; Martin G πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 142 KB

Background: Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based